Approval · Notice of Compliance 22288 · 2019
VASERETIC: Notice of Compliance 22288
Issued June 14, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22288
- Date
- June 14, 2019
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Labelling Only
- Reason
- To update the Product Monograph with information about the new adverse event non-melanoma skin cancer observed during and after use of hydrochlorothiazide, in response to an Advisement Letter issued by Health Canada
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VASERETIC | Not yet assigned | — |
Medicinal ingredients
- HYDROCHLOROTHIAZIDE 25 MG per TAB
- ENALAPRIL SODIUM 8 MG per TAB